Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition).
Vol 22, No 14S (July 15 Supplement), 2004: 7318
© 2004 American Society of Clinical Oncology

This Article Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Abacioglu, U. Articles by Turhal, N. S. Search for Related Content PubMed Articles by Abacioglu, U. Articles by Turhal, N. S.

Abstract

Results of concurrent chemoradiotherapy (CRT) with low dose weekly gemcitabine (G) in stage III non-small cell lung cancer (NSCLC)

Marmara University, Istanbul, Turkey

7318

Background: Combined CRT is the treatment of choice for stage III NSCLC. G is a novel deoxycitidine analogue that has been proven to be a potent radiosensitizer. To demonstrate the tolerability and efficacy of low dose G given weekly as a radiosensitizer in stage III NSCLC, 22 patients were treated with concurrent CRT. Patients and Methods: Patients with KPS 70, adequate bone marrow reserve, without prior RT and surgery were included. Eighteen patients had received prior induction CT. G (75 mg/m²/week) was infused over 1 hour for 6 weeks. Two hours later thoracic RT was given over 6 weeks with 1.8 Gy/day (total dose 61.2 Gy). Pulmonary toxicity was evaluated with CT scans 6 weeks after RT and treated accordingly. Results: Median follow-up was 15 months (range, 2–40). Half of the patients had stage IIIA disease. Median age was 60 years (range, 48–75), 68% were male and median KPS was 90. Conformal 3D RT planning was used in 64% of patients. G was given for a median of 5.5 weeks (range, 1–9). Twelve patients (54.6%) received all planned CT. G was stopped because of intolerance (grade 2 nausea/vomiting, neutropenia and grade 3 esophagitis) in 6 and death in 2 patients. Eight patients (36.4%) had radiation pneumonitis, 7 were grade 1/2 and 1 was grade 5. One patient (4.5%) had clinical CR, 81.8% had PR while 9.1% had SD. Sixteen patients died, 6 with progression of primary, 8 due to metastatic disease, 1 with pulmonary toxicity and another one with cerebrovascular accident. Conclusion: Gemcitabine used as radiosensitizer during the primary RT of stage III NSCLC patients is a promising agent revealing increased local control with tolerable toxicity profile in patients with good performance status.

View larger version (11K): [in this window] [in a new window]